UPDATE: BMO Capital Maintains Gilead Sciences (GILD) at Market Perform (Correction)

November 2, 2016 6:56 AM EDT
Get Alerts GILD Hot Sheet
Price: $72.70 +0.94%

Rating Summary:
    24 Buy, 11 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade GILD Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
(Updated - November 2, 2016 7:17 AM EDT)

(Gilead was not upgraded to Outperform, remains Market Perform at BMO.)

BMO Capital maintained its Market Perform rating on Gilead Sciences (NASDAQ: GILD) with a price target of $84 (prior $98). Comments follow Q3 results.

Analyst M. Ian Somaiya said, "We are lowering our price target to $84 from $98, reflecting continued weakness in HCV sales despite the strength of the TAF STR product launches in HIV. We believe that recent failure of simtuzumab in its P2 trial in NASH cirrhotics increases reliance on the early stage pipeline. We believe a slowdown in share repurchasing, a recent $5B debt financing, and $31.6B in cash could support a significant acquisition, as we continue to believe Gilead's next key catalyst remains business development as management needs to fill its pipeline gap."

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $74.07 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change, Upgrades

Related Entities

BMO Capital, Definitive Agreement

Add Your Comment